FRAZIER MANAGEMENT LLC
SEATTLE, WA · CIK 1032165 · 13F filing filed 2021-08-11
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Legal entityFRAZIER MANAGEMENT, L.L.C. (US)
- Others nearbySeattle, WA
As an employer
US visa salary filings
- Filings FY20251
- Median salary offered$125,000
- Middle half$125,000 – $125,000
- Job titles1
| Job title | Filings | Median |
|---|---|---|
| Associate, Investment AnalystSeattle, WA | 1 | $125,000 |
Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Frazier Management LLC.
$1.1bn
reported value
-13.0% vs Q1 2021
34positions
78.0%in top 10
2 new
1 added
8 reduced
3 sold out
vs Q1 2021
Holdings, Q2 2021
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC ARQT | $230.2m21.23% | Reduced -2.1m |
| PHATHOM PHARMACEUTICALS INC PHAT | $197.3m18.19% | Unchanged |
| PASSAGE BIO INC COM | $66.3m6.12% | Unchanged |
| MIRUM PHARMACEUTICALS INC MIRM | $61.7m5.69% | Unchanged |
| TRANSLATE BIO INC COM | $57.4m5.29% | Reduced -100.0k |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $55.6m5.13% | Added +825.0k |
| KRYSTAL BIOTECH INC KRYS | $53.6m4.94% | Reduced -107.1k |
| VAXCYTE INC PCVX | $52.0m4.79% | Unchanged |
| TARSUS PHARMACEUTICALS INC TARS | $41.1m3.79% | Reduced -500.0k |
| TRILLIUM THERAPEUTICS INC TR | $30.3m2.79% | Unchanged |
| ANAPTYSBIO INC ANAB | $23.3m2.15% | Unchanged |
| ALPINE IMMUNE SCIENCES INC NVLS | $23.1m2.13% | Unchanged |
| SYNDAX PHARMACEUTICALS INC SNDX | $20.4m1.88% | Reduced -246.9k |
| SUTRO BIOPHARMA INC COM | $18.6m1.72% | Unchanged |
| IVERIC BIO INC OPHT | $16.1m1.48% | Unchanged |
| CHINOOK THERAPEUTICS INC ADRO | $15.5m1.43% | New |
| AUTOLUS THERAPEUTICS PLC AUTL | $15.2m1.40% | New |
| FRAZIER LIFESCIENCES ACQU CO UNIT 12/09/2025 | $15.1m1.39% | Unchanged |
| REGENXBIO INC RGNX | $13.7m1.26% | Unchanged |
| MOLECULAR TEMPLATES INC COM | $10.7m0.99% | Unchanged |
| GRITSTONE BIO INC GRTS | $9.4m0.87% | Unchanged |
| ESSA PHARMA INC EPI | $9.0m0.83% | Unchanged |
| ACLARIS THERAPEUTICS INC ACRS | $6.5m0.60% | Reduced -325.3k |
| EPIZYME INC EPZM | $6.1m0.57% | Unchanged |
| APTINYX INC COM | $5.3m0.49% | Reduced -1.3m |
| SCHOLAR ROCK HLDG CORP SRRK | $4.5m0.42% | Unchanged |
| FREELINE THERAPEUTICS HLDGS SPONSORED ADS | $4.5m0.41% | Unchanged |
| ALLENA PHARMACEUTICALS ALNA | $4.3m0.40% | Unchanged |
| BELLUS HEALTH INC NEW BLU | $4.0m0.37% | Unchanged |
| SIERRA ONCOLOGY INC COM NEW | $3.9m0.36% | Unchanged |
| AVADEL PHARMACEUTICALS PLC SPONSORED ADR | $3.9m0.36% | Unchanged |
| IMMUNOVANT INC IMVT | $2.7m0.25% | Reduced -254.0k |
| GALERA THERAPEUTICS INC COM | $2.4m0.22% | Unchanged |
| NABRIVA THERAPEUTICS PLC SHS | $575.0k0.05% | Unchanged |
Sold out since Q1 2021
| Security | Value then |
|---|---|
| ADVERUM BIOTECHNOLOGIES INC | $14.2m1.4m shares |
| CARDIFF ONCOLOGY INC CRDF | $2.7m293.5k shares |
| ITERUM THERAPEUTICS PLC ITRMF | $2.2m1.5m shares |